|
Recommendation for
Cilostazol |
|
COR |
LOE |
Recommendation |
|
I |
A |
Cilostazol is an effective
therapy to improve symptoms and increase walking distance in
patients with claudication.199,200
|
|
See Online Data Supplement
25. |
In a Cochrane review including 15
double-blind RCTs with a total of 3718 participants, cilostazol was
associated with improvement in claudication symptoms but no changes
in cardiovascular deaths or QoL when compared with
placebo.199 In 1 RCT, cilostazol was more effective than
pentoxifylline or placebo.200 Side effects include headache, abnormal
stool (diarrhea), dizziness, and palpitations. Cilostazol is
contraindicated in patients with congestive heart failure.201 In 1 trial,
20% of patients discontinued cilostazol within 3
months.202
|
|